- Home
- DAVE vs HAE Comparison
DAVE vs HAE Comparison
Compare DAVE & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVE | HAE |
|---|---|---|
| Founded | 2017 | 1971 |
| Country | United States | United States |
| Employees | 280 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | DAVE | HAE |
|---|---|---|
| Price | $227.56 | $65.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $312.75 | $84.13 |
| AVG Volume (30 Days) | 362.7K | ★ 808.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $26.28 | N/A |
| Revenue Next Year | $17.38 | $5.23 |
| P/E Ratio | ★ $17.85 | $25.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $152.21 | $47.32 |
| 52 Week High | $287.69 | $87.32 |
Technical Indicators
Market Signals| Indicator | DAVE | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 67.49 |
| Support Level | $226.74 | $49.26 |
| Resistance Level | $252.69 | $66.86 |
| Average True Range (ATR) | 16.48 | 3.28 |
| MACD | -4.26 | 1.02 |
| Stochastic Oscillator | 5.50 | 96.53 |
Price Performance
Historical ComparisonAbout DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, short-term liquidity, fee-free banking, and financial management tools, and finding side gigs.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.